Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
Condition: Ulcerative Colitis
MeSH terms: Colitis; Colitis, Ulcerative; Ulcer
Intervention: MMX Mesalamine
Intervention description: MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
Intervention MeSH terms: Mesalamine
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 290.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: ulcerative colitis; compliance; mesalamine; clinical study; clinical trial; clinical research; maintenance; long term; uc study; uc trial; uc research; open label; once a day; once; daily; daily dosing; simple; oral

Summary:

      To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX
      mesalamine once daily.
    

Eligibility criteria:

        Inclusion Criteria - Acute Phase:

          1. Male and female subjects aged at least 18 years with active mild to moderate UC may
             enter the Acute Phase of the study.

          2. Must have a previous diagnosis of UC confirmed by histology and endoscopy or
             radiology.

          3. Males or non-pregnant, non-lactating FOCP who have a negative serum pregnancy test
             prior to entering the study and who are using adequate forms of contraception for the
             duration of the study.

          4. General medical assessment must be satisfactory and there must not be clinically
             significant and relevant abnormalities.

          5. Subject must have had >2 acute episodes of UC (a documented episode of increased bowel
             frequency with rectal blood loss for which UC therapy was intensified) in their
             medical history.

          6. Subjects who have relapsed on maintenance therapy after 2 weeks with doses of
             mesalamine at: a. <2.0g/day, will be allowed into the Acute Phase at 2.4g/day QD, or
             b. between 2.0g/day - 3.0g/day will be allowed into the Acute Phase at 4.8g/day QD.

        Inclusion Criteria - Maintenance Phase:

          1. Subjects determined to be quiescent at study entry on prior oral mesalamine therapy
             will be eligible to enter directly into the Maintenance Phase.

          2. UC must have been considered to be quiescent, with scores of zero for both rectal
             bleeding and bowel movements.

        Exclusion Criteria - Acute Phase:

          1. Subjects who have been in relapse for >6 weeks.

          2. Female subjects who are pregnant or lactating, including females with a positive
             pregnancy test at screening.

          3. Subjects must not have used another investigational agent within the last 30 days
             prior to enrollment.

          4. Subjects who have unsuccessfully treated their current relapse with steroids or a
             mesalamine dose of >2.0 g/day.

          5. Subjects who have relapsed on maintenance therapy with doses of mesalamine >2.0g/day.
             If the subject had a recent dose reduction from 2.0g/day to less than or equal to
             2.0g/day and relapsed within 2 weeks of that dose reduction, the subject will not be
             eligible.

          6. Subjects who have used systemic or rectal steroids within the last 4 weeks prior to
             Baseline, immunosuppressants within the last 6 weeks, antibiotic use within the last 7
             days or chronic use of any anti-inflammatory drugs within 7 days prior to Baseline.

          7. Subjects with hypersensitivity to salicylates/aspirin are excluded.

          8. Subjects with moderate or severe hepatic impairment.

          9. Subjects with Crohn's Disease, proctitis (where the extent of inflammation is less
             than or equal to 15cm), short bowel syndrome, bleeding disorders, or active peptic
             ulcer disease.

         10. Subjects with asthma are excluded only if they are known to be mesalamine-sensitive.

         11. Subjects with a positive stool culture for enteric pathogens (including Salmonella,
             Shigella, Yersinia, Aeromonas, Plesiomonas or Campylobacter) are excluded, as are
             those with C. difficile toxin present or with ova or parasites as detected by
             microscopy.

         12. Subjects who have a history of previous colonic surgery.

         13. Subjects with moderate or severe renal impairment are contra-indicated for treatment
             with mesalamine compounds and are excluded from the study.

         14. Subjects with current or recurrent disease that could affect the colon, the action,
             absorption or disposition of the study drug, or clinical or laboratory assessments.

         15. Subjects with current or relevant previous history of serious, severe or unstable
             (acute or progressive) physical or psychiatric illness, any medical disorder that may
             require treatment or make the patient unlikely to fully complete the study, or any
             condition that presents undue risk from the study drug or procedures.

         16. Subjects with a history of alcohol or other substance abuse within the previous year.

         17. Subjects who withdrew from a mesalamine trial due to a possibly or probably related
             severe AE or SAE are not eligible to enter this study.

        Exclusion Criteria - Maintenance Phase (in addition to above inclusion for the Acute
        Phase):

          1. Subjects who have withdrawn from the Acute Phase before study visit A3.

          2. Subjects with severe UC according to the PGA.